BBPWM
DNA icon

Blue Bell Private Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

Blue Bell Private Wealth Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7
Closed -$69 – 731
2024
Q4 		$69 Hold
7
– – ﹤0.01% 672
2024
Q3 		$57 Sell
7
-1
-13% -$10 ﹤0.01% 683
2024
Q2 		$100 Hold
8
– – ﹤0.01% 709
2024
Q1 		$348 Hold
8
– – ﹤0.01% 711
2023
Q4 		$507 Hold
8
– – ﹤0.01% 702
2023
Q3 		$543 Hold
8
– – ﹤0.01% 658
2023
Q2 		$558 Hold
8
– – ﹤0.01% 670
2023
Q1 		$399 Hold
8
– – ﹤0.01% 651
2022
Q4 		$507 Hold
8
– – ﹤0.01% 672
2022
Q3 		$1K Hold
8
– – ﹤0.01% 660
2022
Q2 		$1K Hold
8
– – ﹤0.01% 708
2022
Q1 		$1K Hold
8
– – ﹤0.01% 770
2021
Q4 		$2K Buy
+8
New +$3.8K ﹤0.01% 667

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Blue Bell Private Wealth Management's DNA Position: Q1 2025 in Review

Blue Bell Private Wealth Management sold out of Ginkgo Bioworks (DNA) in Q1 2025, closing a stake of 7 shares — an estimated $69 sold.

Blue Bell Private Wealth Management first reported a position in DNA in Q4 2021 and held it in 13 quarters. The position peaked at $2K in Q4 2021. 167 funds tracked by Wall St. Rank hold DNA as of Q1 2025.

  • Blue Bell Private Wealth Management reported no remaining Ginkgo Bioworks position as of Q1 2025 after selling out during the quarter.
  • Blue Bell Private Wealth Management sold 7 Ginkgo Bioworks shares in Q1 2025, an estimated $69.
  • Blue Bell Private Wealth Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 13 quarters.
  • Blue Bell Private Wealth Management's Ginkgo Bioworks position peaked at $2K in Q4 2021.
  • 167 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2025.

Based on Blue Bell Private Wealth Management's 13F filing for Q1 2025, filed 5 May 2025.